Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK MPs wants pharma in AIDS patent pool, while GSK makes new moves

This article was originally published in Scrip

Executive Summary

The prices of newer second-line antiretroviral treatments (ARTs) need to be urgently reduced to improve access to developing countries, says a new report by a group of UK members of Parliament. The report, The Treatment Timebomb, states that by 2030 more than 50 million people will need ARTs worldwide, compared with just nine million today.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts